Aasld 2024 Abstract Class

Aasld 2024 Abstract Class. This trial evaluated the efficacy and safety of investigational elafibranor, an oral, dual ppar α,δ agonist, as a potential novel class of treatment for patients with the rare,. Submit your abstract for the world’s premier #hepatology event.


Aasld 2024 Abstract Class

The liver meeting brings together clinicians, associates, and scientists from around the world to exchange information on the latest research, discuss new developments in liver treatment and. Aasld foundation abstract awards recognize excellence and promote the professional development of early career investigators.

Aasld 2024 Abstract Class Images References :